Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 M(pro), Impairing Variants Replication In Vitro and In Vivo

Atazanavir (ATV) has already been considered as a potential repurposing drug to 2019 coronavirus disease (COVID-19); however, there are controversial reports on its mechanism of action and effectiveness as anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Through the pre-clinical ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Chaves, Otávio Augusto, Sacramento, Carolina Q., Ferreira, André C., Mattos, Mayara, Fintelman-Rodrigues, Natalia, Temerozo, Jairo R., Vazquez, Leonardo, Pinto, Douglas Pereira, da Silveira, Gabriel P. E., da Fonseca, Laís Bastos, Pereira, Heliana Martins, Carlos, Aluana Santana, d’Avila, Joana C., Viola, João P. B., Monteiro, Robson Q., Bozza, Patrícia T., Castro-Faria-Neto, Hugo Caire, Souza, Thiago Moreno L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777605/
https://www.ncbi.nlm.nih.gov/pubmed/35056078
http://dx.doi.org/10.3390/ph15010021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777605/
https://www.ncbi.nlm.nih.gov/pubmed/35056078
http://dx.doi.org/10.3390/ph15010021

Ejemplares similares